ArticleAnnals of surgical oncology2025
Indocyanine Green Fluorescence-Guided Axillary Reverse Mapping for Axillary Lymph Node Dissection in Breast Cancer: The FARM Trial.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymphedema is a significant complication following axillary lymph node dissection (ALND). Axillary reverse mapping (ARM) is a technique aimed at identifying and preserving lymphatic drainage of the upper limb during ALND to prevent lymphedema. However, concerns regarding tracer reliability and oncological safety have hindered its widespread use. This study assessed feasibility of indocyanine green fluorescence-guided ARM during ALND and explored predictive factors for ARM node metastasis.
methodsIn this prospective trial (ACTRN12621000817842), patients with clinically node-positive breast cancer or positive sentinel lymph node biopsy requiring ALND (2022-2025) were enrolled. Indocyanine green was injected into the upper arm to visualize lymphatics using near-infrared fluorescence during ALND. Axillary reverse mapping nodes were categorized by anatomical zone based on intersection of lateral thoracic vein (vertical) and second intercostobrachial nerve (horizontal). Axillary reverse mapping nodes were sent separately for histopathological analysis. Univariate and multivariate analyses were performed on patient, tumor, and nodal characteristics.
resultsAmong 100 patients, ARM nodes were identified in 95% (95% confidence interval [CI] 88.7-98.4), yielding 111 nodes. Of these, 68.5% were located in the upper lateral axilla. Metastatic involvement of ARM nodes occurred in 18.9% of cases. Multivariate analysis identified tumor size ≥ 50 mm (hazard ratio [HR] 1.98, 95% confidence interval [CI] 0.25-3.83, p = 0.04) and higher nodal stage (N2/N3) (HR 3.04, 95% CI 1.37-4.58, p = 0.015) as independent predictors of ARM node metastasis.
conclusionsIndocyanine green fluorescence-guided ARM is a feasible technique during ALND. However, the risk of ARM node metastasis in advanced disease suggests that routine ARM node preservation may be unsafe, indicating the need for alternative strategies, such as lymphaticovenous anastomosis, to mitigate lymphedema risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.